1. Home
  2. XELB vs AKTX Comparison

XELB vs AKTX Comparison

Compare XELB & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Xcel Brands Inc.

XELB

Xcel Brands Inc.

HOLD

Current Price

$1.55

Market Cap

10.6M

Sector

Miscellaneous

ML Signal

HOLD

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

HOLD

Current Price

$0.13

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XELB
AKTX
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.6M
11.5M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
XELB
AKTX
Price
$1.55
$0.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$3.00
$2.53
AVG Volume (30 Days)
42.2K
339.7K
Earning Date
11-19-2025
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$83.93
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.74
$0.13
52 Week High
$4.20
$1.58

Technical Indicators

Market Signals
Indicator
XELB
AKTX
Relative Strength Index (RSI) 49.26 26.92
Support Level $1.51 N/A
Resistance Level $1.60 $0.27
Average True Range (ATR) 0.19 0.03
MACD 0.02 -0.01
Stochastic Oscillator 63.04 3.31

Price Performance

Historical Comparison
XELB
AKTX

About XELB Xcel Brands Inc.

Xcel Brands Inc is a media and brand management company. It is engaged in design, merchandising and planning, sourcing and production, licensing, marketing, and brand development. The company offers branded apparel, footwear, accessories, jewelry, home goods, and other consumer products. Its brand portfolio consists of the Isaac Mizrahi, Judith Ripka, H Halston, C Wonder, and the Highline Collective brands. The company licenses its brands to third parties, provides certain designs, production, and marketing services, and generates licensing, design, and service fee revenues through contractual arrangements and other agreements.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

Share on Social Networks: